focus -WSS

focus

author：explore 2025-09-28 23:47:37 - browse：15962

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： FogPharma raises $145 million in rare Series E round

WSS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Medicare explains how it will choose drugs for negotiation

Medical device lobby: We're tired of waiting on Medicare coverage

Kenai launches with $82 million for Parkinson’s stem cell therapy

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Radiation, mainstay of cancer treatment, begins a fade

knowledge

focus

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Kenai launches with $82 million for Parkinson’s stem cell therapy

Alkermes shareholders re

An inside look at PIPEs, biotech's buzzy new financing tool

Dobbs anniversary: the lost opportunity of abortion as health care

Departing Stanford president retracts two papers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Departing Stanford president retracts two papers

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Biotech companies concerned about China biosecurity crackdown

explore

How to make Best Hospitals ratings actually useful for patients

Why getting cancer drugs just got harder for rural patients

Flu vaccine offering decent levels of protection this winter, new data show

Radiation, mainstay of cancer treatment, begins a fade

RaDonda Vaught to speak at CommonSpirit event on patient safety

FDA panel gives mixed vote on blood pressure devices

explore

knowledge

entertainment

hotspot